BPC-157: research overview

The short version

BPC-157 is a fifteen-amino-acid peptide (a pentadecapeptide, meaning fifteen amino acids in a chain) derived from a protein found in human gastric juice. Researchers gave it the name Body Protection Compound 157. It is not an approved medicine anywhere. The reason it attracts attention in recovery and repair research is that in a large body of animal experiments, it consistently seems to accelerate healing across several tissue types — tendons, gut lining, muscle, even blood vessels — and the most well-characterized explanation is that it promotes the growth of new blood vessels (angiogenesis). Whether that translates reliably to people is a genuinely open question: as of 2025, controlled human trials are essentially absent, and a handful of small pilot reports are all that exists on the human side ^[2].

What it is

Structurally, BPC-157 is a synthetic fifteen-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that reproduces a partial stretch of a protein isolated from human gastric juice. It is sometimes called Pentadecapeptide BPC 157, PL 14736, or Bepecin in the research literature. Its molecular formula is C62H98N16O22. One formal pharmacokinetics study in rats and dogs found it has a very short elimination half-life (under thirty minutes), modest intramuscular bioavailability, and is rapidly broken down into small amino acid fragments that enter normal metabolic pathways ^[3].

BPC-157 is not a growth hormone. It is not a hormone of any kind. It is a cytoprotective research peptide — the term cytoprotection means protecting cells from damage — whose repair effects in animals are mechanistically linked to blood-vessel biology rather than the pituitary-growth-hormone axis.

In 2023 the US Food and Drug Administration placed BPC-157 in a category of substances it identified as not eligible for pharmacy compounding under 503A rules, pending further review. It is also prohibited at all times in competitive sport by the World Anti-Doping Agency under its category for non-approved substances.

How it works

The most clearly characterized mechanism is pro-angiogenic signaling through VEGFR2, the vascular endothelial growth factor receptor. A 2017 study in chick chorioallantoic membranes, rat hindlimb ischemia models, and human vascular endothelial cells found that BPC-157 up-regulates VEGFR2 expression and promotes its internalization, triggering the downstream VEGFR2-Akt-eNOS (nitric oxide synthase) pathway ^[4]. The result, in those models, was increased vessel density and faster blood-flow recovery in ischemic muscle.

Additional reported pathways, less thoroughly characterized, include FAK-paxillin signaling (which governs cell migration), sensitization of the growth hormone receptor in tendon fibroblasts, and modulation of the serotonergic and dopaminergic systems through what is sometimes called the brain-gut axis ^[7]. A 2016 review by Sikiric and colleagues frames BPC-157 as a mediator of cytoprotection that reaches from gut to central nervous system via these neurotransmitter connections, involving Egr-1, NAB2, FAK-paxillin, and JAK-2 pathways ^[7]. The nitric oxide system appears in several of these accounts as a convergence point.

All of this mechanism work is primarily rodent or cell-line data. Its relevance to human physiology awaits controlled investigation.

What the research shows

The preclinical record for BPC-157 is broad and largely consistent, while the human record is almost nonexistent.

Animal findings:

In a foundational gastric ulcer study in Wistar rats, BPC-157 reduced ulcer area and accelerated healing at the epithelial and granulation-tissue level, with intramuscular delivery outperforming intragastric ^[5]. In a transected Achilles tendon model, also in Wistar rats, it accelerated healing across biomechanical, functional, and microscopic measures, and stimulated tendocyte (tendon cell) outgrowth in parallel cell-culture experiments ^[6]. The blood-vessel mechanism study extended these findings to ischemic limb recovery, directly linking the effect to VEGFR2 ^[4].

Pharmacokinetics:

The first formal ADME (absorption, distribution, metabolism, excretion) study characterized BPC-157 in rats and dogs ^[3]. Key findings: linear pharmacokinetics, elimination half-life under thirty minutes, intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, excretion mainly via urine and bile. The peptide breaks rapidly into small fragments.

Human data:

A 2025 first-in-human intravenous safety pilot administered BPC-157 up to 20 mg in two healthy adults — a 58-year-old man and a 68-year-old woman ^[1]. No adverse events were observed; cardiac, hepatic, renal, thyroid, and glucose biomarkers remained unchanged. The authors are explicit that this is a tiny, uncontrolled pilot, not an efficacy trial.

A 2025 narrative review surveying the full BPC-157 literature concluded that 'only three pilot studies have examined BPC-157 in humans' and that 'rigorous, large-scale trials are lacking' ^[2]. It recommends treating the compound as investigational and notes that much of the foundational animal literature comes from a single research group, limiting independent replication. Whether the broad, consistent animal findings translate to people, and at what conditions or quantities, remains genuinely unknown.

Reported effects, cautions and safety

Anecdotal, not clinical evidence. The following describes what people in research-use communities report. These are personal accounts and informal surveys, not results from controlled human trials.

Commonly reported as beneficial:

• Faster recovery from tendon, ligament and joint injuries — this is the primary reason people in research-use communities try BPC-157. They describe stubborn tendon and joint problems feeling better and more usable, often within the first one to three weeks.
• Less joint stiffness and pain — day-to-day joint stiffness easing and painful movements becoming easier.
• Improved digestive or gut symptoms — less bloating, cramping, and urgency, and better tolerance of foods that previously caused discomfort.
• Faster skin and wound healing — a smaller group reports that minor wounds seemed to close faster, connecting this to the compound's reported angiogenic effect.
• Better sleep, mood or stress tolerance — occasionally reported; commentators suggest this could reflect less pain, a calmer gut, or placebo rather than a direct brain effect.

Commonly reported as adverse:

• Injection-site redness, stinging, or a small bump — the most common complaint; described as brief and minor.
• Nausea or mild stomach upset — more common with oral or sublingual products than injections; often passes in a few days.
• Fatigue or tiredness in the first week — an anecdotal pattern that many say settles on its own.
• Headache — mild and transient; one of the more frequently mentioned minor complaints.
• Dizziness or lightheadedness shortly after injecting — some attribute this to the peptide's reported effect on blood vessels and the nitric oxide system.
• Heart palpitations or a racing feeling — rarely reported; commentators treat persistent rapid heartbeat or chest pain as reasons to seek medical evaluation.

Safety cautions from the literature:

The human evidence is extremely thin ^[2]. Because BPC-157's repair effects are tied to angiogenesis, there is a theoretical (mechanism-based, not human-trial-derived) concern that strong pro-angiogenic activity could be unhelpful in the presence of active or suspected cancer ^[4]. In rodent work the peptide modulates serotonin activity, raising a theoretical question about interactions with serotonin-raising medicines; this caution is preclinical, not from human interaction studies ^[7]. Growth hormone receptor sensitization in tendon fibroblasts raises a similar long-term theoretical question about unwanted tissue growth ^[6]. Long-term human safety data simply do not exist. BPC-157 is not verified for purity or identity through regulated channels and is prohibited in sport by WADA.

Where it fits in everyday recovery research

Within the recovery-and-repair frame of this desk, BPC-157 occupies the vascular corner. Its studied mechanisms point to promoting blood vessel growth into damaged or ischemic tissue — the supply-side of repair. GHK-Cu, by contrast, sits in the matrix corner (building the scaffolding), and KPV sits in the inflammatory corner (quieting the signals that can stall recovery). The three describe repair from different angles.

BPC-157's breadth in animal work — tendon, gut, muscle, nerve, vascular — is unusual for a research peptide; it is the reason it appears as the lead compound here. Its weakness is the one shared by most research peptides: the animal-to-human translation gap is real, and the human evidence is still at the pilot stage.

For context on how BPC-157 compares with GHK-Cu and KPV across evidence type, regulatory status, and research focus, see the comparison page.